Avience Biomedicals Hits Upper Circuit After 90% Listing Pop on NSE SME Debut

Mumbai, June 25: Avience Biomedicals share price extended its dream run on the NSE SME platform, hitting the upper circuit soon after a blockbuster listing that saw the stock surge nearly 90% over its issue price. The strong debut was followed by continued buying interest, with the stock locked in upper circuit limits as momentum traders and retail participants piled in.  

The stock IPO-ed at Rs 208 per share, listed at Rs 395.20 per share and rose 5 per cent to hit the upper circuit limit at Rs 414.95. 

Blockbuster listing sparks immediate momentum

The stock’s listing performance came significantly ahead of expectations, with Avience Biomedicals debuting at a steep premium over its IPO price. The nearly 90% listing gain reflected strong demand during the subscription phase, which had already signaled aggressive investor appetite.  

The stock surged and froze on debut after a stellar listing and IPO. Source: NSE 

The sharp debut also aligned with buoyant sentiment typically seen in select SME IPOs, where limited supply and high demand can amplify price moves on listing day. 

Following the listing pop, the stock continued its upward trajectory, hitting upper circuits as early investors and short-term traders sought to ride the momentum. The sustained buying interest highlighted strong speculative participation in the counter, with limited floating stock further intensifying price action.  

The initial public offering was subscribed 365.06 times on June 22, the final day of bidding. 

Avience Biomedicals had aimed to raise Rs 30.2 crore through the IPO of 14.53 lakh shares. The price band was Rs 196-208 per share. 

Healthcare and diagnostics theme draws investor interest

Avience Biomedicals makes in-vitro diagnostic (IVD) products and medical devices, a segment that has increasingly attracted investor attention due to its exposure to preventive healthcare, laboratory testing, and diagnostic services. The company’s positioning in a niche healthcare segment added to the IPO narrative, supporting strong demand during the primary issue phase.

Investor enthusiasm around healthcare-related SMEs has been relatively strong, particularly for companies seen as benefiting from long-term structural growth in diagnostics and medical testing. This thematic appeal has played a key role in driving oversubscription and strong listing-day performance for select issues in the segment. 

SME listings remain highly momentum-driven

While the rally underscores strong market appetite, SME listings are often characterised by heightened volatility and limited liquidity. In such stocks, sharp post-listing gains are frequently driven by momentum rather than sustained fundamental re-rating, especially in the initial trading sessions. 

Market participants note that price discovery in SME counters can be rapid and exaggerated due to lower free float and concentrated buying interest. This often results in extended upper circuits or equally sharp reversals once initial enthusiasm normalises.

Volatility likely to stay elevated post listing

Going forward, Avience Biomedicals is expected to remain volatile as the market moves from listing-driven momentum to more fundamental price discovery. While early gains highlight strong demand, investors typically watch for stabilisation in volumes and valuation comfort before taking longer-term positions. 

Overall, the stock’s debut reflects the continued appetite for SME IPOs in India, where strong listings can generate significant short-term wealth creation, even as longer-term performance depends on earnings visibility and sustained business execution. 

Source: 

• https://www.nseindia.com/get-quote/equity/AVIENCE/Avience-Biomedicals-Limited